Predicting and Manipulating Cardiac Drug Inactivation by the Human Gut Bacterium Eggerthella lenta
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Digoxin Dangers: A proportion of patients treated with digoxin, a cardiac glycoside used to treat heart function abnormalities, generate the inactive metabolite, dihydrodigoxin, resulting in poor efficacy. Haiser et al. (p. 295 ) examined a potential culprit responsible for this transformation—the actinobacterium, Eggerthella lenta —to probe the microbiota-digoxin interaction. Microbe growth was promoted by arginine, and differential expression analysis revealed a two-gene cardiac glycoside reductase ( cgr ) operon that was induced by digoxin in low arginine conditions. Not all strains of E. lenta could reduce digoxin and, when fecal samples from healthy people were tested, a spectrum of digoxin inactivation was detected. When the digoxin-reducing strain of E. lenta was given to germ-free mice that were fed a high-protein (that is, high-arginine) diet, digoxin levels stayed high in serum, and drug inactivation was suppressed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Notably, the cgr ratio could be used to effectively discriminate microbial communities exhibiting low versus high digoxin reduction (Fig. 5).”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [67]
The cited source says what the claim attributes to it.
In the citing paper
“The amino acid arginine prevents digoxin inactivation by E. lenta in vitro, decreasing the expression and activity of the genes responsible (the cgr operon)67.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [67]
The cited source says what the claim attributes to it.
In the citing paper
“Because the intestine is a major site for drug metabolism (both by cytochrome P-450 enzymes in intestinal epithelial cells and by the gut microbiome87)”
From Microfluidic Organ-on-a-Chip Models of Human Intestine (2018) · cites this paper as [87]
The cited source says what the claim attributes to it.
In the citing paper
“Taken together, this functional metabolic repertoire includes the capacity for clinically relevant activation (e.g., sulfasalazine) (Peppercorn and Goldman, 1972b), reactivation (e.g., irinotecan/SN-38) (Wallace et al., 2010), and detoxification (e.g., digoxin) (Haiser et al., 2013) of xenobiotics with broad implications for drug action and toxicity (see Table 1).”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Haiser et al., 2013
The cited source says what the claim attributes to it.
In the citing paper
“was inducible by the drug it metabolizes (Haiser et al., 2013).”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Haiser et al., 2013
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primer3—new capabilities and interfaces
Untergasser, A., Cutcutache, I., Koressaar, T., Ye, J., Faircloth, B. C., Remm, M., & Rozen, S. G. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks596 · Cited by 9,461
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Versatile and open software for comparing large genomes
Kurtz, S., Phillippy, A., Delcher, A. L., Smoot, M., Shumway, M., Antonescu, C., & Salzberg, S. L. (2004) · Genome Biology · doi:10.1186/gb-2004-5-2-r12 · Cited by 5,254
Breitling, R., Armengaud, P., Amtmann, A., & Herzyk, P. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.07.055 · Cited by 1,496
Isolation of a Bacterium That Reductively Dechlorinates Tetrachloroethene to Ethene
Maymó-Gatell, X., Chien, Y.-T., Gossett, J. M., & Zinder, S. H. (1997) · Science · doi:10.1126/science.276.5318.1568 · Cited by 1,125
Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., et al. (2010) · Science · doi:10.1126/science.1191175 · Cited by 1,080
SSAHA: A Fast Search Method for Large DNA Databases
Ning, Z., Cox, A. J., & Mullikin, J. C. (2001) · Genome Research · doi:10.1101/gr.194201 · Cited by 965
Xenobiotics shape the physiology and gene expression of the active human gut microbiome
Maurice, C. F., Haiser, H. J., & Turnbaugh, P. J. (2013) · Cell · doi:10.1016/j.cell.2012.10.052 · Cited by 811
A Catalog of Reference Genomes from the Human Microbiome
The Human Microbiome Jumpstart Reference Strains Consortium, Nelson, K. E., Weinstock, G. M., Highlander, S. K., Worley, K. C., Creasy, H. H., Wortman, J. R., Rusch, D. B., Mitreva, M., Sodergren, E., et al. (2010) · Science · doi:10.1126/science.1183605 · Cited by 702
Inactivation of Digoxin by the Gut Flora: Reversal by Antibiotic Therapy
Lindenbaum, J., Rund, D. G., Butler, V. P., Tse-Eng, D., & Saha, J. R. (1981) · New England Journal of Medicine · doi:10.1056/nejm198110013051403 · Cited by 423
Cited by
Items 201–300 of 704
Advancing the Microbiome Research Community
Huttenhower, C., Knight, R., Brown, C. T., Caporaso, J. G., Clemente, J. C., Gevers, D., Franzosa, E. A., Kelley, S. T., Knights, D., Ley, R. E., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.022 · Cited by 58
“…drug responses, such as the role of specific strains of the gut Actinobacterium Eggerthella lenta in inactivating the cardiac glycoside drug digoxin (Haiser et al., 2013) and of p-cresol production by certain gut bacteria interfering with host detoxification of acetaminophen (Clayton et al., 2009).”
From Sample to Multi-Omics Conclusions in under 48 Hours
Quinn, R. A., Navas-Molina, J. A., Hyde, E. R., Song, S. J., Vázquez-Baeza, Y., Humphrey, G., Gaffney, J., Minich, J. J., Melnik, A. V., Herschend, J., et al. (2016) · mSystems · doi:10.1128/msystems.00038-16 · Cited by 61
Advancing gut microbiome research using cultivation
Sommer, M. O. A. (2015) · Current Opinion in Microbiology · doi:10.1016/j.mib.2015.08.004 · Cited by 71
Exploring Drug Metabolism by the Gut Microbiota: Modes of Metabolism and Experimental Approaches
Dhurjad, P., Dhavaliker, C., Gupta, K., & Sonti, R. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000669 · Cited by 66
“This was a unique case where dietary intervention reverses the metabolism by gut microbes(Haiser et al., 2013).”
BackgroundWang, S., Ju, D., & Zeng, X. L. (2024) · Biomedicines · doi:10.3390/biomedicines12010194 · Cited by 73
“For instance, Eggerthella can metabolize digoxin into inactive forms [44].”
Plichta, D. R., Somani, J., Pichaud, M., Wallace, Z. S., Fernandes, A. D., Perugino, C. A., Lähdesmäki, H., Stone, J. H., Vlamakis, H., Chung, D. C., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00853-7 · Cited by 59
The Microbiota, Chemical Symbiosis, and Human Disease
Redinbo, M. R. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.09.011 · Cited by 59
Exploring the potential impact of probiotic use on drug metabolism and efficacy
Purdel, C. N., Ungurianu, A., Adam-Dima, I., & Margina, D. M. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114468 · Cited by 71
Tralau, T., Sowada, J., & Luch, A. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.990437 · Cited by 58
“For example, while being a ubiquitous commensal not all strains of Eggerthella lenta carry the catabolic digoxin-operon [98], suggesting the latter to be a niche-specific adaptation for substrate usage.”
BackgroundThe Role of the Microbiome in Drug Response
Pryor, R. E., Martínez‐Martínez, D., Quintaneiro, L. M., & Cabreiro, F. (2019) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023612 · Cited by 59
Kamath, S., Stringer, A. M., Prestidge, C. A., & Joyce, P. M. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2233900 · Cited by 60
“This metabolite has reduced affinity for Na+/K+ ATPase expressed in heart tissue leading to 20-fold reduced activity [26,43]; thus, dihydrodigoxin is considered cardio-inactive.”
BackgroundMethodInfluentialIntegrating the gut microbiome and pharmacology
Verdegaal, A. A., & Goodman, A. L. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg8357 · Cited by 71
“Bacterial drug-metabolizing activities can activate prodrugs ( 74 ), decrease serum drug exposure ( 3 , 16 , 75 – 78 ), or increase exposure to microbial drug metabolites ( 3 , 18 ) or may have no effect on drug pharmacokinetics depending on the sites of absorption, microbial activity, and other…”
BackgroundResultInfluentialMicrobial biotransformations in the human distal gut
Bik, E. M., Ugalde, J. A., Cousins, J., Goddard, A. D., Richman, J., & Apte, Z. S. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14085 · Cited by 62
“Digoxin, a drug used to treat congestive heart failure, can be inactivated by Eggerthella lenta strains that carry the cgr operon in their genome (Haiser et al., 2013).”
BackgroundGut bacterial deamination of residual levodopa medication for Parkinson’s disease
van Kessel, S. P., de Jong, H. R., Winkel, S. L., van Leeuwen, S. S., Nelemans, S. A., Permentier, H., Keshavarzian, A., & El Aidy, S. (2020) · BMC Biology · doi:10.1186/s12915-020-00876-3 · Cited by 56
Insights from pharmacokinetic models of host-microbiome drug metabolism
Zimmermann‐Kogadeeva, M., Zimmermann, M., & Goodman, A. L. (2019) · Gut Microbes · doi:10.1080/19490976.2019.1667724 · Cited by 60
Psycho-Pharmacomicrobiomics: A Systematic Review and Meta-Analysis
Minichino, A., Preston, T., Fanshawe, J. B., Fusar‐Poli, P., McGuire, P. K., Burnet, P. W. J., & Lennox, B. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.07.019 · Cited by 65
“Human gut bacteria can convert pro-medications into active compounds 110 (6), inactivate medications (7), influence their enterohepatic recirculation via β-D111 glucuronidases (8), and affect their absorption via secondary bile acids and blockage of 112 intestinal P-glycoproteins(9).”
BackgroundThe human gut chemical landscape predicts microbe-mediated biotransformation of foods and drugs
Guthrie, L., Wolfson, S., & Kelly, L. (2019) · eLife · doi:10.7554/elife.42866 · Cited by 55
“Reduction of digoxin by a human microbiome reductase inactivates the drug, contributing to poor bioavailability in some individuals (Haiser et al., 2013; Haiser et al., 2014; Lindenbaum et al., 1981).”
BackgroundMicrobiota and Colorectal Cancer: From Gut to Bedside
Silva, M. G., Brunner, V., & Tschurtschenthaler, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.760280 · Cited by 66
A data-driven approach for predicting the impact of drugs on the human microbiome
Algavi, Y. M., & Borenstein, E. (2023) · Nature Communications · doi:10.1038/s41467-023-39264-0 · Cited by 54
Precision microbiota therapy for IBD: premise and promise
Nagayama, M., Gogokhia, L., & Longman, R. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2489067 · Cited by 70
Remote Sensing Between Liver and Intestine: Importance of Microbial Metabolites
Fu, Z. D., & Cui, J. Y. (2017) · Current Pharmacology Reports · doi:10.1007/s40495-017-0087-0 · Cited by 56
Obesity and the gut microbiome: pathophysiological aspects
Bradlow, H. L. (2014) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2013-0063 · Cited by 52
“The cardiac drug digoxin is inactivated in the gut by specific strains of Eggerthella lenta, which is inhibited by high arginine concentrations [40].”
BackgroundAziz, R. K., Hegazy, S. M., Yasser, R., Rizkallah, M. R., & ElRakaiby, M. T. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1530216 · Cited by 56
“However, only recently the actual mechanism by which the bacteria degrade digoxin was revealed, and the finding was intriguing because only a few strains of these bacteria were found to possess the cardiac glycoside reductase genes (cgr), which encode the degrading enzymes [59].”
BackgroundDempsey, J. L., Wang, D., Siginir, G., Fei, Q., Raftery, D., Gu, H., & Cui, J. Y. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy271 · Cited by 59
Predicting and Understanding the Human Microbiome’s Impact on Pharmacology
Hitchings, R., & Kelly, L. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.04.014 · Cited by 60
Discovery and mining of enzymes from the human gut microbiome
Jia, B., Han, X., Kim, K. H., & Jeon, C. O. (2021) · Trends in biotechnology · doi:10.1016/j.tibtech.2021.06.008 · Cited by 53
Cornide‐Petronio, M. E., Álvarez‐Mercado, A. I., Jiménez‐Castro, M. B., & Peralta, C. (2020) · Nutrients · doi:10.3390/nu12020284 · Cited by 54
“The human gut microbiota provides an energy source [109], is involved in the synthesis of vitamins and neurotransmitters [110], metabolizes bile salts [111], and eliminates toxins [112].”
BackgroundGut-liver axis: Pathophysiological concepts and medical perspective in chronic liver diseases
Rodrigues, S. G., der Merwe, V., Krag, A. A., & Wiest, R. (2024) · Seminars in Immunology · doi:10.1016/j.smim.2023.101859 · Cited by 57
MASS SPECTROMETRY‐BASED PERSONALIZED DRUG THERAPY
Cui, J., Wang, L., Tan, Z., Zhou, H., Zhan, X., & Yin, J. (2020) · Mass Spectrometry Reviews · doi:10.1002/mas.21620 · Cited by 52
Nanaerobic growth enables direct visualization of dynamic cellular processes in human gut symbionts
García-Bayona, L., Coyne, M. J., Hantman, N., Llopis, P. D. L. M. M., Von, S. S., Ito, T., Malamy, M. H., Basler, M., Barquera, B., & Comstock, L. E. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2009556117 · Cited by 49
Human microbiome science: vision for the future, Bethesda, MD, July 24 to 26, 2013
Ravel, J., Blaser, M. J., Braun, J., Brown, E., Bushman, F. D., Chang, E. B., Davies, J., Dewey, K. G., Dinan, T., Dominguez-Bello, M., et al. (2014) · Microbiome · doi:10.1186/2049-2618-2-16 · Cited by 49
Self-citationUnmasking the tissue-resident eukaryotic DNA virome in humans
Pyöriä, L., Pratas, D., Toppinen, M., Hedman, K., Sajantila, A., & Perdomo, M. F. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad199 · Cited by 54
Cho, G., Ritzmann, F., Eckstein, M., Huch, M., Briviba, K., Behsnilian, D., Neve, H., & Franz, C. M. A. P. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00658 · Cited by 57
“A probe which targeted both the Collinsella and Coriobacterium species (‘Collinsella-group’ probe) showed lower counts of between 4.1× 109 to 7.7× 109 bacteria per gram dry weight feces.”
BackgroundMethodResultInfluentialCurrò, D. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1414598 · Cited by 52
“6 predicts digoxin reduction efficiency with good sensitivity, specificity, and precision [28].”
BackgroundCreekmore, B. C., Gray, J. H., Walton, W. G., Biernat, K. A., Little, M. S., Xu, Y., Liu, J., Gharaibeh, R. Z., & Redinbo, M. R. (2019) · mSystems · doi:10.1128/msystems.00452-19 · Cited by 49
Rocha, B. S., & Laranjinha, J. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.02.001 · Cited by 49
Chemical Metabolism of Xenobiotics by Gut Microbiota
Nakov, R., & Velikova, T. (2020) · Current Drug Metabolism · doi:10.2174/1389200221666200303113830 · Cited by 49
Giacomini, K. M., Yee, S. W., Koleske, M. L., Zou, L., Matsson, P., Chen, E. C., Kroetz, D. L., Miller, M. A., Gozalpour, E., & Chu, X. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2627 · Cited by 46
How to Determine the Role of the Microbiome in Drug Disposition
Bisanz, J. E., Spanogiannopoulos, P., Pieper, L. M., Bustion, A. E., & Turnbaugh, P. J. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.083402 · Cited by 55
Self-citationThe Future of Microbiome‐Based Therapeutics in Clinical Applications
Sharma, A., Das, P., Buschmann, M. M., & Gilbert, J. A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1677 · Cited by 53
“The bacterium Eggerthella lenta carries a cardiac glycoside reductase operon that metabolizes digoxin into inactive metabolites, making the drug ineffective.(26) Further research into this drug’s metabolism led to the discovery of small pockets in the cardiac glycoside reductase operon, which is bound by digoxin.”
BackgroundPredictors of tacrolimus pharmacokinetic variability: current evidences and future perspectives
Degraeve, A. L., Moudio, S., Haufroid, V., Eddour, D. C., Mourad, M., Bindels, L. B., & Elens, L. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1803277 · Cited by 56
The emerging science of precision medicine and pharmacogenomics for Parkinson's disease
Payami, H. (2017) · Movement Disorders · doi:10.1002/mds.27099 · Cited by 47
“The microbiome facilitates the metabolism of prescription drugs (directly via microbial metabolites and indirectly by affecting host xenobiotic metabolism) and can therefore affect the efficacy and toxicity of medications.(65,66) In turn, medications could alter the composition of the microbiome (antibiotics is the cl…”
BackgroundMenozzi, E., & Schapira, A. H. V. (2024) · CNS Drugs · doi:10.1007/s40263-024-01073-4 · Cited by 52
Interplays between drugs and the gut microbiome
Wan, Y., & Zuo, T. (2022) · Gastroenterology report · doi:10.1093/gastro/goac009 · Cited by 48
Dong, X., Guthrie, B. G. H., Alexander, M., Noecker, C. A., Ramirez, L., Glasser, N. R., Turnbaugh, P. J., & Balskus, E. P. (2022) · Nature Communications · doi:10.1038/s41467-022-33576-3 · Cited by 51
“The strain-variable cgr (cardiac glycoside reductase) operon enables E. lenta to inactivate multiple carde-nolides found in toxic plants, including the cardiac drug digoxin 8,9 .”
Self-citationEffects of intestinal flora on pharmacokinetics and pharmacodynamics of drugs
Džidić-Krivić, A., Kusturica, J., Sher, E. K., Selak, N., Osmančević, N., Farhat, E. K., & Sher, F. (2023) · Drug Metabolism Reviews · doi:10.1080/03602532.2023.2186313 · Cited by 49
“Haiser et al. (2013) studied the effect of gut Actinobacterium Eggerthella lenta on the inactivation of a drug often used in cardiology - digoxin.”
BackgroundGut Microbiome-Based Management of Patients With Heart Failure
Mamic, P., Snyder, M. P., & Tang, W. H. W. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.045 · Cited by 53
Translational research into gut microbiota: new horizons on obesity treatment: updated 2014
Tsukumo, D. M. L., Carvalho, B. M., Filho, C., & Saad, M. J. A. (2015) · Archives of Endocrinology and Metabolism · doi:10.1590/2359-3997000000029 · Cited by 53
“Another interesting study in this area is related to the inactivation of cardiac drug digoxin by gut bacteria (Eggerthella lenta), suggesting an important role of diet and microbioma in inducing digitalis intoxication (64).”
Quantitative systems pharmacology and the personalized drug–microbiota–diet axis
Thiele, I., Clancy, C. M., Heinken, A., & Fleming, R. M. T. (2017) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2017.06.001 · Cited by 46
Li, L., Zhang, X., Ning, Z., Mayne, J., Moore, J. I., Butcher, J., Chiang, C., Mack, D. R., Stintzi, A., & Figeys, D. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00461 · Cited by 54
Challenges and opportunities of strain diversity in gut microbiome research
Anderson, B., & Bisanz, J. E. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1117122 · Cited by 50
“Eggerthella lenta was known to metabolize the cardiac drug digoxin as early as the 1980s (Dobkin et al., 1982); however, the mechanisms were unknown until 2013 when RNA-seq revealed an operon whose expression was induced by the presence of the drug (Haiser et al., 2013).”
BackgroundMythen, S. M., Devendran, S., Méndez–García, C., Cann, I., & Ridlon, J. M. (2018) · Applied and Environmental Microbiology · doi:10.1128/aem.02475-17 · Cited by 48
“glycosides (19, 20), 21-dehydroxylate corticosteroids (21), hydrolyze conjugated bile 84 acids (22), and oxidize bile acid hydroxyl groups (23,24).”
BackgroundCesare, A. D., Sala, C., Castellani, G., Astolfi, A., Indio, V., Giardini, A., & Manfreda, G. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228338 · Cited by 44
“This species has been described by Haiser et al., 2013 [31] as part of the human gut microbiome.”
BackgroundGut microbiota in reductive drug metabolism
Guo, Y., Lee, H., & Jeong, H. (2020) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2020.04.002 · Cited by 51
GARBH-Ini study group, Mehta, O., Ghosh, T. S., Kothidar, A., Gowtham, M. R., Mitra, R., Kshetrapal, P., Wadhwa, N., Thiruvengadam, R., Nair, G. B., et al. (2020) · Microbial Ecology · doi:10.1007/s00248-020-01501-0 · Cited by 47
Zhou, H. W., Sun, J., Yu, B., Liu, Z., Chen, H., He, J., Mao, X., Zheng, P., Yu, J., Luo, J., et al. (2021) · Animal nutrition · doi:10.1016/j.aninu.2020.11.012 · Cited by 46
Wlodarska, M., Johnston, J. C., Gardy, J. L., & Tang, P. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00124-14 · Cited by 43
Bonham, K. S., Bottino, G. F., McCann, S., Beauchemin, J., Weisse, E., Barry, F., Cano-Lorente, R., Huttenhower, C., Bruchhage, M. M. K., D’Sa, V. A., et al. (2023) · Science Advances · doi:10.1126/sciadv.adi0497 · Cited by 46
Investigation of Host–Gut Microbiota Modulation of Therapeutic Outcome
Yip, L. Y., & Chan, E. C. Y. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.063750 · Cited by 43
“…microbiota is known to affect pharmacokinetics by partaking in the direct metabolism of xenobiotics or through its indirect interaction with the host enzymatic system (Scheline, 1968; Nicholson et al., 2005; Sousa et al., 2008; Clayton et al., 2009; Haiser and Turnbaugh, 2012; Haiser et al., 2013).”
InfluentialMicrobiota and kidney disease: the road ahead
Bloom, P. P., Garrett, W. S., Penniston, K. L., Winkler, M. K. H., Hazen, S. L., Agudelo, J., Suryavanshi, M. V., Babiker, A. Y. M., Dodd, D., Fischbach, M. A., et al. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-00988-5 · Cited by 55
Self-citationNoecker, C. A., Sánchez, J. M., Bisanz, J. E., Escalante, V., Alexander, M., Trepka, K. R., Heinken, A., Liu, Y., Dodd, D., Thiele, I., et al. (2023) · PLoS Biology · doi:10.1371/journal.pbio.3002125 · Cited by 50
“We first confirmed that citrulline, but not ornithine, can replace arginine with nearly equivalent growth in EDM1, replicating a previous result in rich media ([16]; S5A Fig ).”
Self-citationGuo, Y., Chen, M., Li, S. H. A. O., Zhang, W., Rao, T., Zhou, H., & Huang, W. (2019) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(19)30026-3 · Cited by 53
Crosstalk Between the Gut Microbiome and Bioactive Lipids: Therapeutic Targets in Cognitive Frailty
Baptista, L. C. P., Sun, Y., Carter, C. S., & Buford, T. W. (2020) · Frontiers in Nutrition · doi:10.3389/fnut.2020.00017 · Cited by 51
“This system also modulates energy biogenesis (35) and the biosynthesis of vitamins and neuro-transmitters (36), metabolizes bile salts (37), reacts ormodifies specific drugs, and eliminates exogenous toxins (38).”
BackgroundRole of Clinicogenomics in Infectious Disease Diagnostics and Public Health Microbiology
Westblade, L. F., van Belkum, A., Grundhoff, A. T., Weinstock, G. M., Pamer, E. G., Pallen, M. J., & Dunne, W. M. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.02664-15 · Cited by 40
Ostrem Loss, E., Thompson, J., Cheung, P. L. K., Qian, Y., & Venturelli, O. S. (2023) · Nature Ecology & Evolution · doi:10.1038/s41559-022-01930-9 · Cited by 38
Ricaurte, D., Huang, Y., Sheth, R. U., Gelsinger, D. R., Kaufman, A., & Wang, H. H. (2024) · Nature Microbiology · doi:10.1038/s41564-023-01581-x · Cited by 38
“Therefore, transcriptomic measurements can help quickly dissect specific drug–microorganism responses (for example, digoxin 15 , 5-fluorouracil 22 and levodopa 23 ).”
InfluentialThe Future of Pharmacogenomics: Integrating Epigenetics, Nutrigenomics, and Beyond
Shaman, J. A. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14121121 · Cited by 45
Pharmacomicrobiomics: The Role of the Gut Microbiome in Immunomodulation and Cancer Therapy
Bolte, L. A., Björk, J. R., Gaćeša, R., & Weersma, R. K. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.04.025 · Cited by 43
Influence of immunomodulatory drugs on the gut microbiota
Cohen, I., Ruff, W. E., & Longbrake, E. E. (2021) · Translational research · doi:10.1016/j.trsl.2021.01.009 · Cited by 39
Gut Microbiota and Aging: Traditional Chinese Medicine and Modern Medicine
Li, J., Li, D., Chen, Y., Chen, W., Xu, J., & Gao, L. (2023) · Clinical Interventions in Aging · doi:10.2147/cia.s414714 · Cited by 40
Mirror, mirror on the wall: which microbiomes will help heal them all?
Nayak, R. R., & Turnbaugh, P. J. (2016) · BMC Medicine · doi:10.1186/s12916-016-0622-6 · Cited by 36
“For example, we have shown that digoxin is metabolized by select strains of Eggerthella lenta, and gut microbiomes with a higher abundance of the genes responsible for digoxin metabolism have a greater impact on drug levels [52].”
BackgroundSelf-citationArtificial intelligence-driven prediction of multiple drug interactions
Chen, S., Li, T., Yang, L., Zhai, F., Jiang, X., Xiang, R., & Ling, G. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac427 · Cited by 45
Gut Microbiome-Based Therapeutics in Critically Ill Adult Patients—A Narrative Review
He, S., Lin, F., Hu, X., & Pan, P. (2023) · Nutrients · doi:10.3390/nu15224734 · Cited by 36
“For example, gut Actinobacterium Eggerthella lenta could affect the pharmacokinetic of digoxin and reduce its toxicity in treating congestive heart failure [78].”
BackgroundDelving the depths of ‘terra incognita’ in the human intestine — the small intestinal microbiota
Yılmaz, B., & Macpherson, A. J. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-01000-4 · Cited by 41
Prescription drugs obscure microbiome analyses
Devkota, S. (2016) · Science · doi:10.1126/science.aaf1353 · Cited by 36
The complex relationship between drugs and the microbiome
Savage, N. (2020) · Nature · doi:10.1038/d41586-020-00196-0 · Cited by 43
In sickness and health: Effects of gut microbial metabolites on human physiology
Glowacki, R. W. P., & Martens, E. C. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1008370 · Cited by 36
“Two prominent examples are inactivation of the cardiac drug digoxin by Eggerthella lenta [49] and related plant-derived cardenolides [50] and the ability of several species to convert the common dietary compound choline to trimethylamine (TMA), which is subsequently converted by the host to harmful trimethylamine-N-ox…”
BackgroundMachine Learning Predicts Drug Metabolism and Bioaccumulation by Intestinal Microbiota
McCoubrey, L. E., Thomaidou, S., Elbadawi, M., Gaisford, S., Orlu, M., & Basit, A. W. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122001 · Cited by 47
“lenta concentration in patients’ faeces is significantly correlated with their ex vivo metabolism of digoxin, providing strong evidence that patients colonised by CGRencoding bacteria metabolise digoxin to a greater extent in vivo [25].”
BackgroundMetabolic modeling with Big Data and the gut microbiome
Sung, J., Hale, V., Merkel, A. C., Kim, P.-J., & Chia, N. (2016) · Applied & Translational Genomics · doi:10.1016/j.atg.2016.02.001 · Cited by 35
“…of colon cancer (Weir et al., 2013), proteome and metagenome data related to Crohn's disease (Erickson et al., 2012), and metabolome, metagenome, and metatranscriptome data to examine the relationship between the gut microbiome and the xenobiotic metabolism of digoxin (Haiser et al., 2013a, 2013b).”
BackgroundYu, A., Ingelman‐Sundberg, M., Cherrington, N. J., Aleksunes, L. M., Zanger, U. M., Xie, W., Jeong, H., Morgan, E. T., Turnbaugh, P. J., Klaassen, C. D., et al. (2017) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.12.006 · Cited by 37
Self-citationLee, D. H., Seong, H., Chang, D., Gupta, V. K., Kim, J., Cheon, S., Kim, G., Sung, J., & Han, N. S. (2023) · npj Science of Food · doi:10.1038/s41538-023-00195-1 · Cited by 41
Kumar, K., Jaiswal, S. K., Dhoke, G. V., Srivastava, G. N., Sharma, A. K., & Sharma, V. K. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26638 · Cited by 36
The pharmaco-toxicological conundrum of oleander: Potential role of gut microbiome
Dey, P. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110422 · Cited by 41
Optimizing ex vivo culture conditions to study human gut microbiome
Tao, X., Huang, W., Pan, L., Sheng, L., Qin, Y., Chen, L., Yu, L., Wu, G., Wan, J., & Li, H. (2023) · ISME Communications · doi:10.1038/s43705-023-00245-5 · Cited by 40
Clinician Guide to Microbiome Testing
Staley, C. M., Kaiser, T., & Khoruts, A. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5299-6 · Cited by 44
Potential Implications of Gut Microbiota in Drug Pharmacokinetics and Bioavailability
Flowers, S. A., Bhat, S., & Lee, J. C. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2428 · Cited by 42
The Gut Microbiome and Xenobiotics: Identifying Knowledge Gaps
Sutherland, V. L., McQueen, C. A., Mendrick, D. L., Gulezian, D., Cerniglia, C. E., Foley, S. L., Forry, S., Khare, S., Liang, X., Manautou, J. E., et al. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa060 · Cited by 33
Henig, I. J., Yehudai‐Ofir, D., & Zuckerman, T. (2020) · Haematologica · doi:10.3324/haematol.2020.247395 · Cited by 41
Wang, M., Amakye, W. K., Gong, C., Ren, Z., Yuan, E., & Ren, J. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.01.003 · Cited by 38
Leone, V., Cham, C. M., & Chang, E. B. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.08.004 · Cited by 34
Clinical manifestation of macrolide antibiotic toxicity in CKD and dialysis patients
K.‐W., T., Chow, K.-M., Choy, A. S. M., Kwan, B. C., Szeto, C., & Li, P. K.-T. (2014) · Clinical Kidney Journal · doi:10.1093/ckj/sfu098 · Cited by 32
“There is evidence that inactivation of digoxin by the gut actinobacterium Eggerthella lenta to its inactive metabolite, dihydrodigoxin, contributes to around 10% of digoxin metabolism [55, 56].”
BackgroundDrug-microbiota interactions and treatment response: Relevance to rheumatoid arthritis
Sayers, E., MacGregor, A. J., & Carding, S. R. (2018) · AIMS Microbiology · doi:10.3934/microbiol.2018.4.642 · Cited by 36
Current Trends in Experimental and Computational Approaches to Combat Antimicrobial Resistance
Imchen, M., Moopantakath, J., Kumavath, R., Barh, D., Tiwari, S., Ghosh, P., & Azevedo, V. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.563975 · Cited by 38
“Such a rich reservoir of genes house drug-metabolizing genes that can have various effects on the drugs, such as sulfasalazine activation (Sousa et al., 2014), digoxin inactivation (Haiser et al., 2013), and sorivudine toxification (Okuda et al., 1998).”
BackgroundUntapped potential of gut microbiome for hypertension management
Gao, K., Wang, P., Mei, X., Yang, T., & Yu, K. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2356278 · Cited by 40
Pharma[e]cology: How the Gut Microbiome Contributes to Variations in Drug Response
Trepka, K. R., Olson, C. A., Upadhyay, V., Zhang, C., & Turnbaugh, P. J. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022724-100847 · Cited by 36
“A combination of comparative genomics and transcriptomics identified a two-gene operon that is highly induced by digoxin and found only in a subset of E. lenta strains, termed the cardiac glycoside reductase (cgr) operon (17).”
Self-citationMicrobial metabolism marvels: a comprehensive review of microbial drug transformation capabilities
Martinelli, F., & Thiele, I. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2387400 · Cited by 33
“29,30 Further investigation revealed an expanded 8-gene-cgr associated gene cluster with cgr2 being sufficient for digoxin activation.”
BackgroundIdentification of medication–microbiome interactions that affect gut infection
Kumar, A., Sun, R., Habib, B., Deng, T., Bencivenga-Barry, N. A., Palm, N. W., Ivanov, I. I., Tamblyn, R. M., & Goodman, A. L. (2025) · Nature · doi:10.1038/s41586-025-09273-8 · Cited by 34
“Tm infection in mice, and its interaction with the microbiome is well known 21,22 , we selected this drug for further study.”
Caminero, A., Tropini, C., Valles‐Colomer, M., Shung, D. L., Gibbons, S. M., Surette, M. G., Sokol, H., Tomeo, N. J., Alenghat, T., Awoniyi, M., et al. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01100-9 · Cited by 47
“Moreover, gut microorganisms can diminish the efficacy of orally ingested medications that are used in intestinal and extra-intestinal disorders but which are not microbiome-related products 98,104 .”
Thorasin, T., McCartney, A. L., & Hoyles, L. (2014) · Microbiology · doi:10.1099/mic.0.000016 · Cited by 34
GUT Microbiome-GUT Dysbiosis-Arterial Hypertension: New Horizons
Katsi, V. K., Didagelos, M., Skevofilax, S., Armenis, I., Kartalis, A. N., Vlachopoulos, C. V., Karvounis, H. I., & Tousoulis, D. M. (2018) · Current Hypertension Reviews · doi:10.2174/1573402114666180613080439 · Cited by 32
Metadata
- Authors
- Haiser, H. J., Gootenberg, D. B., Chatman, K., Sirasani, G., Balskus, E. P., & Turnbaugh, P. J.
- Affiliations
- Harvard University (US)
- Corresponding author
- Turnbaugh, Peter J.
- Venue
- Science
- Published
- 2013-07-19
- Volume
- 341
- Issue
- 6143
- Pages
- 295-298
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3736355
- OpenAlex
- W2161185495
- Cited by
- 704
- References
- 25
- Citations by year
- 2026: 66 · 2025: 58 · 2024: 64 · 2023: 65 · 2022: 54 · 2021: 59 · 2020: 77 · 2019: 56 · 2018: 56 · 2017: 41 · 2016: 31 · 2015: 31 · 2014: 38 · 2013: 8
- FWCI
- 39.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Canadian Institutes of Health Research (112991_1)
- National Institute of General Medical Sciences (P50GM068763)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK034854)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- Eggerthella lenta, digoxin, drug inactivation, gut microbiota, cytochrome P450, gnotobiotic mice, dietary protein, pharmacokinetics, cardiovascular drugs, human-microbe interactions
- MeSH terms
- Animals, Arginine, Cytochromes, Dietary Proteins, Digoxin, Feces, Germ-Free Life, Humans, Mice, Inbred Strains, Operon, Gene Expression Regulation, Bacterial, Actinobacteria, Gastrointestinal Tract, Mice, Metagenome, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.